Montelukast in hospitalized patients diagnosed with COVID-19.
Ahsan R. Khan,Christian Misdary,Nikhil Yegya-Raman,Sinae Kim,Navaneeth Narayanan,Sheraz Siddiqui,Padmini Salgame,Jared Radbel,Frank De Groote,Carl Michel,Janice M. Mehnert,Caleb Hernandez,Thomas J. Braciale,Jyoti Malhotra,Michael A. Gentile,Michael A. Gentile,Salma K. Jabbour +16 more
Reads0
Chats0
TLDR
It is suggested that montelukast associates with a reduction in clinical deterioration for COVID-19 confirmed patients as measured on the CO VID-19 Ordinal Scale and future efforts should evaluate this potential therapy.Abstract:
Several therapeutic agents have been assessed for the treatment of COVID-19, but few approaches have been proven efficacious. Because leukotriene receptor antagonists, such as montelukast have been...read more
Citations
More filters
Journal ArticleDOI
The roles of lipids in SARS-CoV-2 viral replication and the host immune response.
TL;DR: In this paper, the authors summarize the existing literature on the mechanisms through which these lipid mediators may regulate viral burden in COVID-19 and identify the core areas in which lipids offer therapeutic promise for SARS-CoV-2.
Posted ContentDOI
Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2
Mohammad Afsar,Rohan Narayan,Noor Akhtar,Huma Rahil,Sandeep M. Eswarappa,Shashank Tripathi,Tanweer Hussain +6 more
TL;DR: In this paper, the authors have in silico screened Food and Drug Administration (FDA)-approved drugs against Nsp1-C-ter and find that montelukast sodium hydrate has binding affinity (KD) of 10.8{+/-}0.2 M in vitro and forms a stable complex with it in simulation runs with a binding energy of -76.71{−/-}8.95 kJ/mol.
Journal ArticleDOI
Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2
TL;DR: Montelukast sodium hydrate as discussed by the authors has shown antiviral activity against SARS-CoV-2 with reduced viral replication in HEK cells expressing ACE2 and Vero-E6 cells.
Journal ArticleDOI
Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients
TL;DR: It is demonstrated that montelukast inhibits platelet activation induced by plasma from COVID-19 patients by preventing the surface expression of tissue factor and P-selectin, reducing the formation of circulating monocyte– and granulocyte–platelet aggregates, and, finally, in completely inhibiting the release of TFpos-circulating microvesicles.
Journal ArticleDOI
Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Mangaldeep Dey,Rakesh Singh +1 more
TL;DR: In this paper, the authors summarized the possible therapeutic potential and benefits of using montelukast, a cysteinyl leukotriene 1 (CysLT1) receptor antagonist, to control COVID-19 pathophysiology.
References
More filters
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta,Daniel F. McAuley,Michael Brown,Emilie Sanchez,Rachel Tattersall,Rachel Tattersall,Jessica J Manson +6 more
TL;DR: Re-analysis of data from a phase 3 randomised controlled trial of IL-1 blockade (anakinra) in sepsis, showed significant survival benefit in patients with hyperinflammation, without increased adverse events.
Journal ArticleDOI
Clinical and immunological features of severe and moderate coronavirus disease 2019.
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production, which may be of importance due to their correlation with disease severity in COVID-19.
Journal ArticleDOI
SARS-CoV-2: a storm is raging.
Savannah F. Pedersen,Ya Chi Ho +1 more
TL;DR: Overall, this study characterized the cytokine storm in severe COVID-19 and provides insights into immune therapeutics and vaccine design and the authors found that respiratory distress on admission is associated with unfavorable outcomes.
Journal ArticleDOI
Pathogenesis of COVID-19 from a cell biology perspective.
TL;DR: COVID-19 can be understood by the region of the lung that is infected and can be divided into three phases that correspond to different clinical stages of the disease, which will be confined to the conducting airways and severe disease will involve the gas exchange portion of the lungs.